Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focusing on central nervous system (CNS) disorders, has announced its participation in two upcoming investor conferences. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 12:00pm EDT in New York, NY. Additionally, Praxis will attend the Baird Global Healthcare Conference on September 11, 2024, at 2:35pm EDT, also in New York, NY.
Both presentations will be in a fireside chat format. The company will be available for one-on-one meetings with interested investors during these conferences. A replay of the presentations will be available on Praxis' website for 90 days after the events.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biofarmaceutica in fase clinica che si concentra sui disturbi del sistema nervoso centrale (SNC), ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda presenterà al 26° Congresso Globale di Investimenti Annuale H.C. Wainwright il 9 settembre 2024, alle 12:00 EDT a New York, NY. Inoltre, Praxis parteciperà alla Conferenza Globale sulla Salute di Baird l'11 settembre 2024, alle 14:35 EDT, sempre a New York, NY.
Entrambe le presentazioni si svolgeranno in un formato di conversazione informale. L'azienda sarà disponibile per incontri individuali con investitori interessati durante queste conferenze. Una registrazione delle presentazioni sarà disponibile sul sito web di Praxis per 90 giorni dopo gli eventi.
Praxis Precision Medicines (NASDAQ: PRAX), una empresa biofarmacéutica en etapa clínica que se centra en los trastornos del sistema nervioso central (SNC), ha anunciado su participación en dos próximas conferencias para inversores. La empresa presentará en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright el 9 de septiembre de 2024, a las 12:00 p.m. EDT en Nueva York, NY. Además, Praxis asistirá a la Conferencia Global de Salud Baird el 11 de septiembre de 2024, a las 2:35 p.m. EDT, también en Nueva York, NY.
Ambas presentaciones se realizarán en un formato de charla informal. La empresa estará disponible para reuniones individuales con inversores interesados durante estas conferencias. Una repetición de las presentaciones estará disponible en el sitio web de Praxis durante 90 días después de los eventos.
프랙시스 프리시전 메디슨스(NASDAQ: PRAX) 는 중추신경계(CNS) 장애에 초점을 맞춘 임상 단계의 생명공학 회사로 두 개의 다가오는 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. 이 회사는 2024년 9월 9일 오후 12시(EDT) 뉴욕에서 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에서 발표할 것입니다. 또한, 프랙시스는 2024년 9월 11일 오후 2시 35분(EDT) 뉴욕에서 열리는 베어드 글로벌 헬스케어 회의에 참석할 예정입니다.
두 개의 발표 모두 파이어사이드 채팅 형식으로 진행됩니다. 회사는 이러한 컨퍼런스 중에 관심 있는 투자자와 1:1 미팅을 위해 대기할 것입니다. 발표의 재생은 이벤트 후 90일 동안 프랙시스 웹사이트에서 제공될 것입니다.
Praxis Precision Medicines (NASDAQ: PRAX), une entreprise biopharmaceutique en phase clinique axée sur les désordres du système nerveux central (SNC), a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise présentera lors de la 26e Conférence Annuelle Mondiale des Investissements H.C. Wainwright le 9 septembre 2024, à 12h00 EDT à New York, NY. De plus, Praxis assistera à la Conférence Mondiale sur la Santé de Baird le 11 septembre 2024, à 14h35 EDT, également à New York, NY.
Les deux présentations se dérouleront sous un format de discussion informelle. L'entreprise sera disponible pour des réunions individuelles avec les investisseurs intéressés lors de ces conférences. Une rediffusion des présentations sera disponible sur le site web de Praxis pendant 90 jours après les événements.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Zentralnervensystem (ZNS) Störungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 9. September 2024 um 12:00 Uhr EDT in New York, NY, auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright präsentieren. Zusätzlich wird Praxis am 11. September 2024 um 14:35 Uhr EDT an der Baird Global Healthcare Conference, ebenfalls in New York, NY, teilnehmen.
Beide Präsentationen finden im Fireside-Chat-Format statt. Das Unternehmen steht während dieser Konferenzen für eins-zu-eins-Meetings mit interessierten Investoren zur Verfügung. Eine Aufzeichnung der Präsentationen wird für 90 Tage nach den Veranstaltungen auf der Website von Praxis verfügbar sein.
- None.
- None.
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be attending and presenting at two upcoming conferences:
H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat
Presentation date and time: September 9, 2024 at 12:00pm EDT
Location: Lotte New York Palace Hotel, New York, NY
Webcast: here
Baird Global Healthcare Conference
Format: Fireside Chat
Presentation date and time: September 11, 2024 at 2:35pm EDT
Location: InterContinental Barclay Hotel, New York, NY
The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective H.C. Wainwright and/or Baird representatives to request meetings. A replay of the presentation will be posted, when available, to Praxis’ website on the “Events and Presentations” page under the investor section of the website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When and where is Praxis Precision Medicines (PRAX) presenting at the H.C. Wainwright conference?
What is the format of Praxis Precision Medicines' (PRAX) presentations at the upcoming investor conferences?
How long will the replay of Praxis Precision Medicines' (PRAX) presentations be available on their website?
What type of disorders does Praxis Precision Medicines (PRAX) focus on in their drug development?
How can investors arrange meetings with Praxis Precision Medicines (PRAX) during the conferences?
